United Therapeutics Corporation (NasdaqGS: UTHR)
Health Care · Biotechnology · US
$515.05
-0.67% today · +69.8% 1Y
United Therapeutics Corporation (NasdaqGS: UTHR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $22.24B and employs 1,400 people.
Over the last twelve months the share price has gained 69.8%, trading between 302.19 and 609.35.
Tweenvest scores United Therapeutics Corporation across four factors: quality 79/100, value 19/100, growth 70/100. Its strongest factor is quality.
UTHR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $22.24B
- Revenue (TTM)
- $3.15B
- P/E
- 18.55
- EPS
- 27.95
- Dividend yield
- —
- Beta (5Y)
- 0.56
- 52-week high
- $609.35
- 52-week low
- $302.19
- Avg volume (3M)
- —
- Shares outstanding
- 42.89M
- Employees
- 1,400
- Next earnings
- —
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
- ISIN
- US91307C1027
- Founded
- 1996
- Listed since
- Jun 17, 1999
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $260.63 | -1.94% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $438.87 | -0.76% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.49 | -0.19% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $550.54 | -0.42% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $819.48 | -1.69% |
| argenx SEENXTBR: ARGX | $64.17B | €900.00 | +2.37% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $147.14 | -7.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.